Company: Assembly Biosciences
Job title: Chief Scientific Officer
Dr. Papkoff joined Assembly Bio in April 2018 to lead the microbiome therapeutic programs. She has worked in both pharma and biotech for over 25 years and has broad scientific strategy, executive leadership and business experience. She has deep expertise in cell biology and molecular mechanisms of disease which she has applied to therapeutic and biomarker preclinical discovery & development in oncology, inflammation and autoimmunity. Prior to joining Assembly Biosciences, Dr. Papkoff was Senior Vice President of Research at Evelo Biosciences where she led the preclinical scientific team to discover, validate and nominate microbial therapeutics for clinical development in oncology indications. Prior to Evelo Dr. Papkoff was a founding member of the J&J California Innovation Center where she served as Vice President of Immunology Scientific Innovation for the Janssen Immunology Therapeutic Area focused on inflammatory and autoimmune diseases. Previously, she was CSO of CFD Therapeutics, a cancer-immunology focused antibody therapeutics company she co-founded, and held R&D leadership positions at diaDexus, Inc. and Aventis pharma. Beyond her industry career Dr. Papkoff was a Consulting Professor of Cancer Biology at Stanford for a 10-year period and served terms as grant reviewer as well as Advisory Council Member for the California Breast Cancer Research Program. Dr. Papkoff has a B.A in Biology from University of California Santa Cruz, a PhD in Biology from University of California San Diego & the Salk Institute and was a postdoctoral fellow at Stanford and University of California San Francisco.